Similar articles

• Guidelines for company-sponsored Safety Assessment of Marketed Medicines (SAMM) guidelines. Medicines Control Agency, Committee on Safety of Medicines, Royal College of General Practitioners, British Medical Association and Association of the British Pharmaceutical Industry (November 1993).

  [No authors listed] [No authors listed] Br J Clin Pharmacol. 1994 Aug;38(2):95-7. doi: 10.1111/j.1365-2125.1994.tb04330.x. Br J Clin Pharmacol. 1994. PMID: 7981019 Free PMC article. No abstract available.
• A retrospective survey on the safety of Replenine, a high-purity factor IX concentrate.

  Gascoigne EW, Dash CH, Harman C, Wilmot D. Gascoigne EW, et al. Pharmacoepidemiol Drug Saf. 2004 Mar;13(3):187-95. doi: 10.1002/pds.911. Pharmacoepidemiol Drug Saf. 2004. PMID: 15072119 Clinical Trial.
• Probing the safety of central venous catheters.

  Murray EW. Murray EW. Am J Nurs. 1993 May;93(5):72, 75-6. Am J Nurs. 1993. PMID: 8488905 No abstract available.
• Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.

  Looper YJ. Looper YJ. Curr Opin Drug Discov Devel. 2010 Mar;13(2):247-56. Curr Opin Drug Discov Devel. 2010. PMID: 20205058 Review.
• The Japanese Postmarketing Adverse Event Relief System: A Confluence of Regulatory Science, the Legal System, and Clinical Pharmacology.

  Tominaga T, Miyazaki S, Oniyama Y, Weber AD, Kondo T. Tominaga T, et al. Clin Pharmacol Ther. 2017 Aug;102(2):277-282. doi: 10.1002/cpt.537. Epub 2016 Dec 7. Clin Pharmacol Ther. 2017. PMID: 27737512 Review.